AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
The FDA granted two Breakthrough Therapy Designations to AbbVie's c-Met-directed ADC telisotuzumab adizutecan (Temab-A; ABBV-400), one for refractory metastatic CRC with bevacizumab and one for c-Met-expressing EGFR wild-type NSCLC as monotherapy. The designations are AbbVie's first BTDs for Temab-A, bringing its ADC portfolio to four total, and were based primarily on the first-in-human M21-404 study.
Key figures
- Drug Name
- telisotuzumab adizutecan (Temab-A; ABBV-400)
- Phase Of Trial
- Phase 3 and Phase 2/3 studies ongoing
- Btd count
- 2
- Adc portfolio btds
- 4
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.